Last reviewed · How we verify

NCT06032975: MITO45-ProFFiT

PRO for Fighting FT in Ovarian Cancer

Recruiting now Last updated 13 November 2023
What this trial tests

trial testing Questionnaires in Ovarian Cancer in 240 participants. Currently enrolling.

Timeline
30 October 2023
Primary endpoint
1 September 2026
1 September 2027

Quick facts

Lead sponsorNational Cancer Institute, Naples
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment240
Start date30 October 2023
Primary completion1 September 2026
Estimated completion1 September 2027
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute, Naples

Who can join

Eligibility, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for OC patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients.
    Arenare L, Porta C, Barberio D, Terzolo S, et al · · 2023 · cited 14× · PMID 38052104 · DOI 10.1016/j.esmoop.2023.102192

Verify or expand the search:

Other trials of Questionnaires

Trials testing the same drug.

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

Other National Cancer Institute, Naples trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06032975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing